NEURAXIS, INC. Research and Development Expense
NEURAXIS, INC. (NRXS) reported Research and Development Expense of $274.34 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- NEURAXIS, INC. research and development expense for the quarter ending 2026-06-30 was $274.34K, a 138.15% increase year-over-year.
- NEURAXIS, INC. research and development expense for the quarter ending 2026-03-31 was $99.57K, a 15.53% decline year-over-year.
- NEURAXIS, INC. research and development expense for the quarter ending 2025-12-31 was $146.18K, a 5.60% increase year-over-year.
- NEURAXIS, INC. research and development expense for the quarter ending 2025-09-30 was $130.85K, a 3.65% increase year-over-year.
- NEURAXIS, INC. research and development expense for fiscal 2025 was $493.61K, a 13.84% increase from fiscal 2024.
- NEURAXIS, INC. research and development expense for fiscal 2024 was $433.61K, a 156.10% increase from fiscal 2023.
- NEURAXIS, INC. research and development expense for fiscal 2023 was $169.31K, a 24.95% decline from fiscal 2022.
- NEURAXIS, INC. research and development expense for fiscal 2022 was $225.61K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $274.34K 10-Q · filed 2026-08-11 | $373.91K 10-Q · filed 2026-08-11 | $520.09K derived: sum of 3 quarters · filed 2026-08-11 | $650.94K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $99.57K 10-Q · filed 2026-05-12 | $245.75K derived: sum of 2 quarters · filed 2026-05-12 | $376.60K derived: sum of 3 quarters · filed 2026-05-12 | $491.79K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $146.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $277.03K derived: sum of 2 quarters · filed 2026-03-19 | $392.23K derived: sum of 3 quarters · filed 2026-08-11 | $493.61K 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $130.85K 10-Q · filed 2025-11-10 | $246.05K derived: sum of 2 quarters · filed 2026-08-11 | $347.43K 10-Q · filed 2025-11-10 | $502.34K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $115.20K 10-Q · filed 2026-08-11 | $58.32K 10-Q · filed 2025-08-12 | $222.20K 10-Q · filed 2026-08-11 | $108.01K 10-Q · filed 2025-08-12 | $371.49K derived: sum of 3 quarters · filed 2026-08-11 | $497.74K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $117.87K 10-Q · filed 2026-05-12 | $60.56K 10-Q · filed 2025-05-12 | $256.29K derived: sum of 2 quarters · filed 2026-05-12 | $382.54K derived: sum of 3 quarters · filed 2026-05-12 | $436.85K derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $138.43K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $264.67K derived: sum of 2 quarters · filed 2026-03-19 | $318.99K derived: sum of 3 quarters · filed 2026-03-19 | $433.61K 10-K · filed 2026-03-19 | $206.11K 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $126.25K 10-Q · filed 2025-11-10 | $72.42K 10-Q · filed 2024-11-12 | $180.56K derived: sum of 2 quarters · filed 2025-11-10 | $295.19K 10-Q · filed 2025-11-10 | $132.30K 10-Q · filed 2024-11-12 | $183.91K derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $54.31K 10-Q · filed 2025-08-12 | $59.88K 10-Q · filed 2025-08-12 | $57.66K derived: sum of 3 quarters · filed 2025-08-12 | $102.61K derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $5.57K 10-Q · filed 2025-05-12 | $3.35K derived: sum of 2 quarters · filed 2025-05-12 | $48.30K derived: sum of 3 quarters · filed 2025-05-12 | $158.09K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$2.22K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $42.73K derived: sum of 2 quarters · filed 2025-03-20 | $152.52K derived: sum of 3 quarters · filed 2025-03-20 | $169.31K 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $44.95K 10-Q · filed 2024-11-12 | $154.74K derived: sum of 2 quarters · filed 2024-11-12 | $171.54K 10-Q · filed 2024-11-12 | $252.91K derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $109.79K 10-Q · filed 2024-08-09 | $126.59K 10-Q · filed 2024-08-09 | $207.96K derived: sum of 3 quarters · filed 2024-08-09 | $294.13K derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $16.80K 10-Q · filed 2024-05-20 | $98.17K derived: sum of 2 quarters · filed 2024-05-20 | $184.34K derived: sum of 3 quarters · filed 2024-05-20 | $198.01K derived: sum of 4 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | $81.37K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $167.55K derived: sum of 2 quarters · filed 2024-04-16 | $181.21K derived: sum of 3 quarters · filed 2024-04-16 | $225.61K 10-K · filed 2024-04-16 | ||||
| 2022-09-30 | $86.17K 10-Q · filed 2023-11-20 | $99.84K derived: sum of 2 quarters · filed 2023-11-20 | $144.24K 10-Q · filed 2023-11-20 | |||||
| 2022-06-30 | $13.66K 10-Q · filed 2023-09-22 | $58.06K 10-Q · filed 2023-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| EDAP TMS SA (FOCL) | $0.171B | ||
| IRIDEX CORP (IRIX) | United States | $0.011B |